Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2008-10-31FDA Approved: TOVIAZ — Original Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved Toviaz (fesoterodine fumarate) from Pfizer as an oral treatment for adults with overactive bladder to relieve symptoms such…
-
FDA approval · 2008-10-29FDA Approved: VESICARE — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for Vesicare (solifenacin succinate) submitted by Astellas Pharma US, Inc.
-
CLINICAL_TRIALS trial_result · 2008-10-16Clinical Trial Update: Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase [Phase 2]
Phase 2 extension study assessing the safety and tolerability of sustained-release fesoterodine (SP668) in subjects with overactive bladder,…
-
CLINICAL_TRIALS trial_result · 2008-10-07Clinical Trial Update: A Two-Part Study to Determine: Best Medication Formulation and Food Effect [Phase 1]
Phase 1 two-part study by GlaxoSmithKline to determine the best medication formulation and food effect for an overactive bladder agent; the …
-
FDA approval · 2008-09-11FDA Approved: DETROL LA — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for DETROL LA (tolterodine tartrate) from Viatris Specialty LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2008-09-11FDA Approved: TOLTERODINE TARTRATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for tolterodine tartrate filed by Mylan Pharmaceuticals Inc.
-
CLINICAL_TRIALS research · 2008-07-28Clinical Trial Update: A Cost Analysis of Interstim Therapy
A completed clinical trial update presenting a cost analysis of Interstim Therapy for urinary retention and symptoms of overactive bladder.
-
CLINICAL_TRIALS trial_result · 2008-06-17Clinical Trial Update: Programmable Timer in the Bladder Rehabilitation Treatment of OAB [NA]
A clinical trial update indicating the study on a programmable timer for bladder rehabilitation in overactive bladder and urinary incontinen…
-
CLINICAL_TRIALS trial_result · 2008-06-17Clinical Trial Update: Surface Nerve Stimulation Treatment for OAB in Children [NA]
A clinical trial evaluating surface nerve stimulation for pediatric overactive bladder and urinary incontinence has completed.
-
CLINICAL_TRIALS trial_result · 2008-06-04Clinical Trial Update: Safety And Efficacy Of Solifenacin In Men With Overactive Bladder (OAB) And Detrusor Underactivity
This clinical trial update reports the safety and efficacy of solifenacin in men with overactive bladder and detrusor underactivity; the stu…
-
CLINICAL_TRIALS trial_result · 2008-05-05Clinical Trial Update: A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome [Phase 3]
A multicenter Phase 3 trial evaluating fesoterodine sustained release for overactive bladder has completed.
-
CLINICAL_TRIALS trial_result · 2008-04-10Clinical Trial Update: A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients [Phase 3]
A Phase 3 double-blind, head-to-head trial comparing solifenacin to tolterodine in overactive bladder has completed.
-
CLINICAL_TRIALS trial_result · 2008-04-10Clinical Trial Update: Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome [Phase 3]
Phase 3 trial evaluating fesoterodine sustained release for overactive bladder has completed, assessing efficacy, tolerability, and safety.
-
CLINICAL_TRIALS trial_result · 2008-04-01Clinical Trial Update: Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity [Phase 2, Phase 3]
Clinical trial update indicating completion of a Phase 2/Phase 3 study evaluating topical estrogens and antimuscarinics for detrusor overact…
-
CLINICAL_TRIALS trial_result · 2008-03-31Clinical Trial Update: A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring [Phase 3]
Phase 3 study evaluating tolterodine extended-release versus propiverine for overactive bladder in Korean patients, assessed by ambulatory u…
-
CLINICAL_TRIALS trial_result · 2008-02-25Clinical Trial Update: Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity [Phase 2]
Phase 2 trial of AV608 for idiopathic detrusor overactivity (overactive bladder) evaluated safety and efficacy; the study was terminated.
-
FDA approval · 2008-02-19FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for oxybutynin chloride by Teva Pharmaceuticals USA, resulting in changes to the existing approved p…
-
FDA approval · 2008-02-08FDA Approved: VESICARE — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for Vesicare (solifenacin succinate) from Astellas Pharma US, Inc., advancing a change to the produc…
-
CLINICAL_TRIALS trial_result · 2008-01-29Clinical Trial Update: Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence [Phase 3]
Phase 3 clinical trial of propiverine in children with non-neurogenic overactive bladder and urinary incontinence has completed.
-
CLINICAL_TRIALS trial_result · 2008-01-24Clinical Trial Update: Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder [Phase 4]
Phase 4 clinical trial sponsored by Novartis evaluated darifenacin with behavioral therapy for symptoms of overactive bladder and has comple…
-
CLINICAL_TRIALS trial_result · 2008-01-23Clinical Trial Update: A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder. [Phase 3]
A Phase 3 clinical trial evaluating darifenacin for increasing warning time in patients with overactive bladder has completed.
-
CLINICAL_TRIALS trial_result · 2008-01-17Clinical Trial Update: A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder [Phase 3]
Phase 3 long-term safety, tolerability and efficacy study of darifenacin in adults with overactive bladder; the trial status is completed.
-
CLINICAL_TRIALS trial_result · 2008-01-15Clinical Trial Update: Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder [Phase 4]
A Phase 4 trial evaluates how patients perceive treatment outcomes with darifenacin for overactive bladder.
-
CLINICAL_TRIALS trial_result · 2007-09-26Clinical Trial Update: Posterior Tibial Nerve Stimulation vs. Sham [Phase 3]
A Phase 3 trial comparing posterior tibial nerve stimulation to sham in adults with overactive bladder has completed.
-
CLINICAL_TRIALS trial_result · 2007-08-08Clinical Trial Update: ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB) [Phase 2]
A Phase 2 randomized trial comparing ELB245 to tolterodine in patients with incontinent overactive bladder was terminated.